Medicine in the Digital Era: Legal Aspects of the Use of Cell and Gene Therapy in Foreign Countries

Abstract

The paper examines the experience of legal regulation of the use of cell and gene therapy products, including CAR-T technologies, in the Anglo-Saxon legal system. It is noted that a significant obstacle to the development of CAR-T therapy, as well as cell and gene therapy in general, is the absence in most countries of the world of comprehensive legal regulation of the use of such innovative methods of treating diseases. Currently, this problem is relevant for the Russian Federation, where cell and gene therapy drugs are actively being developed. The paper provides a detailed overview of the main relevant documents from Australia, the United States of America and Canada, analyzes specific cases illustrating successful law enforcement practice, and examines the mechanisms of self-regulation in the area under study. In conclusion, the authors formulate the key problems and ways to improve legal regulation as to cell and gene therapy drugs application in the Russian Federation. The authors recommend that the best practices of these foreign countries be used, taking into account its critical understanding for the development of appropriate regulatory regulation in the Russian Federation and integration associations with its participation.